Yong Yu Liu

Summary

Affiliation: University of Louisiana at Monroe
Country: USA

Publications

  1. ncbi Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA
    Int J Oncol 39:425-31. 2011
  2. ncbi Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    Cancer Res 71:6295-9. 2011
  3. ncbi Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
    Adv Cancer Res 117:59-89. 2013
  4. ncbi Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71201, USA
    Cancer Res 71:2276-85. 2011
  5. ncbi Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    Mol Cancer 9:145. 2010
  6. ncbi A role for ceramide in driving cancer cell resistance to doxorubicin
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Ave, Monroe, LA 71209, USA
    FASEB J 22:2541-51. 2008
  7. ncbi Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase
    Vineet Gupta
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
    J Lipid Res 51:866-74. 2010
  8. ncbi Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells
    Vineet Gupta
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    J Biol Chem 287:37195-205. 2012
  9. ncbi A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis
    Gauri A Patwardhan
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana, United States of America
    PLoS ONE 4:e6938. 2009
  10. ncbi Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES)
    Akhtar Siddiqui
    Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209 0497, USA
    Int J Pharm 431:222-9. 2012

Collaborators

Detail Information

Publications21

  1. ncbi Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA
    Int J Oncol 39:425-31. 2011
    ..Although a small study, these data suggest that GCS may be a prognostic indicator and potential target for the treatment of chemotherapy-refractory breast cancer...
  2. ncbi Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    Cancer Res 71:6295-9. 2011
    ..A posttranscriptional process that can turn on wild-type p53 expression and abrogate mutant p53 may provide a new strategy to eradicate mutant p53 cancers...
  3. ncbi Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
    Adv Cancer Res 117:59-89. 2013
    ..These studies not only expand our knowledge in understanding how ceramide glycosylation affects cancer cells but also provide novel therapeutic approaches for targeting refractory tumors...
  4. ncbi Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71201, USA
    Cancer Res 71:2276-85. 2011
    ....
  5. ncbi Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    Mol Cancer 9:145. 2010
    ..Understanding the molecular mechanisms underlying MDR1 overexpression and how it interacts with GCS may find effective approaches to reverse drug resistance...
  6. ncbi A role for ceramide in driving cancer cell resistance to doxorubicin
    Yong Yu Liu
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Ave, Monroe, LA 71209, USA
    FASEB J 22:2541-51. 2008
    ..These data indicate that ceramide-governed GCS gene expression drives cellular resistance to doxorubicin...
  7. ncbi Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase
    Vineet Gupta
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
    J Lipid Res 51:866-74. 2010
    ..These data indicate that this cell-based fluorescent method is direct, reproducible, and simple for assessing ceramide glycosylation. It is applicable to validate GCS activity in drug-resistant cancers and in other disorders...
  8. ncbi Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells
    Vineet Gupta
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana 71209, USA
    J Biol Chem 287:37195-205. 2012
    ..It speculates that disruption of ceramide glycosylation or globo-series GSL is a useful approach to specifically target BCSCs specifically...
  9. ncbi A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis
    Gauri A Patwardhan
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, Louisiana, United States of America
    PLoS ONE 4:e6938. 2009
    ..This study, for the first time in vivo, has demonstrated that GCS is a promising therapeutic target for cancer drug resistance, and MBO-asGCS has the potential to be developed as an antineoplastic agent...
  10. ncbi Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES)
    Akhtar Siddiqui
    Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209 0497, USA
    Int J Pharm 431:222-9. 2012
    ..5% for cells treated with both 5 μM doxorubicin SLN and 100 nM MBO-asGCS SLN. This suggested enhanced apoptosis due to sensitization and effective intracellular delivery of MBO-asGCS and doxorubicin by SLN...
  11. ncbi Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy
    Gauri Patwardhan
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA 71209, USA
    Biochem Pharmacol 80:72-9. 2010
    ..Further validation of this method in clinic settings for the diagnosis of drug resistance purpose is needed...
  12. ncbi The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase
    Kaustubh N Bhinge
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA 71209, USA
    Int J Biochem Cell Biol 44:1770-8. 2012
    ..These results indicate that Dox may have opposite effects, suppressing BMSCs versus expanding BCSCs, and GCS is one determinant of the differentiated responsiveness of bone marrow and cancer cells...
  13. ncbi Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells
    Vineet Gupta
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, USA
    Methods Mol Biol 716:179-91. 2011
    ..Flow cytometry analysis of CSCs is a reliable, effective, and easy-handling approach to screen agents targeting CSCs...
  14. ncbi Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells
    Akhtar Siddiqui
    Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209 0497, United States
    Int J Pharm 400:251-9. 2010
    ..These results suggested that SLN enhanced internalization and uptake of MBO-asGCS oligonucleotide, which led to the downregulation of GCS and subsequently reversing the resistance of the cells to doxorubicin...
  15. ncbi In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity
    Xiao Lin Li
    Department of Cellular Biology and Anatomy, Gene Therapy Program, Louisiana State University Health Sciences Center, Shreveport, LA, USA
    Tumour Biol 29:359-70. 2008
    ..Thus, our animal cell model together with the identified genes may provide a useful tool to study ovarian cancer immune response, tumorigenicity and tumor-host cell interactions in the tumor microenvironment...
  16. ncbi Sphingolipids and expression regulation of genes in cancer
    Gauri A Patwardhan
    Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA
    Prog Lipid Res 50:104-14. 2011
    ..These studies not only expand our knowledge of sphingolipids, but can also suggest novel targets for cancer treatments...
  17. ncbi Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy
    Valerie Gouaze
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Mol Cancer Ther 3:633-9. 2004
    ..A possible connection between glucosylceramide synthase and P-gp in drug resistance biology is suggested...
  18. ncbi Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells
    Yong Yu Liu
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    J Lipid Res 45:933-40. 2004
    ..This study demonstrates that a 20-mer asGCS oligonucleotide effectively reverses MDR in human cancer cells...
  19. ncbi Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs
    Valerie Gouaze
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California 90404, USA
    Cancer Res 65:3861-7. 2005
    ..The data suggest that lipids play a role in the expression of multidrug resistance...
  20. ncbi N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing
    Hongtao Wang
    Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Mol Cancer Ther 7:2967-76. 2008
    ..These studies suggest that enhanced clinical efficacy of 4-HPR may be realized through regimens containing agents that modulate sphingoid base metabolism...
  21. ncbi Development of a mammalian Tet-on expression cell line: glucosylceramide synthase regulates TNF-alpha-induced apoptosis
    Yong-Yu Liu
    John Wayne Cancer Institute at Saint John's Health Center, Santa Monic, California, USA
    Methods Mol Biol 249:177-92. 2004